Clinical trial
Salirasib for Treatment of Advanced Non-Small Cell Lung Cancer: a Phase II Study
NCT00531401 is registered in ClinicalTrials.gov with Concordia Pharmaceuticals, Inc as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Salirasib for Treatment of Advanced Non-Small Cell Lung Cancer: a Phase II Study
- Lead sponsor
- Concordia Pharmaceuticals, Inc
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- September 30, 2007
- Completion date
- November 30, 2009
- Enrollment
- 71 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.